Skip to main content

Advertisement

SpringerLink
Log in

The effect of 5-α reductase inhibitor on Th1, Th2, and Th17 cell-related inflammatory response in BPH

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Objective

To investigate the effect of 5-α reductase inhibitor on the expression of inflammation-related cytokines in Benign prostatic hyperplasia (BPH) specimens after transurethral prostatic resection (TUR-P).

Methods

We prospectively examined the expression of inflammation-related cytokines with immunohistochemistry in the paraffin blocks of 60 patients who underwent TUR-P. 30 cases in the 5-α-reductase inhibitor group were treated with finasteride, 5 mg qd, for more than 6 months; 30 cases in the control group were not treated with medicine before operation. HE staining was used to analyze the difference of inflammation reaction between the two groups, and immunohistochemical staining was used to analyze the effect of 5-α reductase inhibitor on the expression of B-cell lymphoma-2 (Bcl-2), Interleukin-2 (IL-2), Interferon-γ (IFN-γ), Interleukin-4 (IL-4), Interleukin-6 (IL-6), Interleukin-17 (IL-17), Interleukin-21 (IL-21) and Interleukin-23 (IL-23) in prostatic tissue.

Results

There was no statistical difference in the location, range and degree of inflammation between the two groups (P > 0.05). When IL-17 expression was low, there was statistical difference between the two groups (P < 0.05). Bcl-2 expression was positively correlated with IL-2, IL-4, IL-6 and IFN-γ (P < 0.05). There was no statistical difference in the expression of IL-21, IL-23 and high expression of IL-17 between the two groups (P > 0.05).

Conclusions

5-α Reductase inhibitor can inhibit the expression of Bcl-2 in prostatic tissue and the inflammatory response related to T-helper cell 1 (Th1) and T-helper cell 2 (Th2) cells. However, it did not affect Th17 cell-related inflammatory response.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data availability

The data underlying this article will be shared on reasonable request to the corresponding author.

References

  1. Agarwal A, Eryuzlu LN, Cartwright R et al (2014) What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women. Eur Urol 65:1211–1217

    Article  PubMed  PubMed Central  Google Scholar 

  2. Andriole G, Bruchovsky N, Chung LW et al (2004) Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 172:1399–1403

    Article  CAS  PubMed  Google Scholar 

  3. Chughtai B, Forde JC, Thomas DD et al (2016) Benign prostatic hyperplasia. Nat Rev Dis Primers 2:16031

    Article  PubMed  Google Scholar 

  4. Nickel JC, Roehrborn CG, O’Leary MP, Bostwick DG, Somerville MC, Rittmaster RS (2008) The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol 54:1379–1384

    Article  PubMed  Google Scholar 

  5. Kruslin B, Tomas D, Dzombeta T, Milkovic-Perisa M, Ulamec M (2017) Inflammation in prostatic hyperplasia and carcinoma-basic scientific approach. Front Oncol 7:77

    Article  PubMed  PubMed Central  Google Scholar 

  6. Hata J, Satoh Y, Akaihata H et al (2016) Molecular classification of benign prostatic hyperplasia: a gene expression profiling study in a rat model. Int J Urol 23:599–612

    Article  CAS  PubMed  Google Scholar 

  7. Fibbi B, Penna G, Morelli A, Adorini L, Maggi M (2010) Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl 33:475–488

    Article  CAS  PubMed  Google Scholar 

  8. McLaren ID, Jerde TJ, Bushman W (2011) Role of interleukins, IGF and stem cells in BPH. Differentiation 82:237–243

    Article  CAS  PubMed  Google Scholar 

  9. Zuniga LA, Jain R, Haines C, Cua DJ (2013) Th17 cell development: from the cradle to the grave. Immunol Rev 252:78–88

    Article  PubMed  Google Scholar 

  10. Arivazhagan J, Nandeesha H, Dorairajan LN, Sreenivasulu K (2017) Association of elevated interleukin-17 and angiopoietin-2 with prostate size in benign prostatic hyperplasia. Aging Male 20:115–118

    Article  CAS  PubMed  Google Scholar 

  11. Liu Y, Zhao X, Sun X et al (2015) Expression of IL-17A, E, and F and their receptors in human prostatic cancer: comparison with benign prostatic hyperplasia. Prostate 75:1844–1856

    Article  CAS  PubMed  Google Scholar 

  12. Nickel JC, True LD, Krieger JN, Berger RE, Boag AH, Young ID (2001) Consensus development of a histopathological classification system for chronic prostatic inflammation. BJU Int 87:797–805

    Article  CAS  PubMed  Google Scholar 

  13. Palmieri C, Hood G, Fonseca-Alves CE, Laufer-Amorim R, Allavena R (2019) An immunohistochemical study of T and B lymphocyte density in prostatic hyperplasia and prostate carcinoma in dogs. Res Vet Sci 122:189–192

    Article  CAS  PubMed  Google Scholar 

  14. Koksoy S, Sahin Z, Karsli B (2013) Comparison of the effects of desflurane and bupivacaine on Th1 and Th2 responses. Clin Lab 59:1215–1220

    Article  CAS  PubMed  Google Scholar 

  15. Hirota K, Martin B, Veldhoen M (2010) Development, regulation and functional capacities of Th17 cells. Semin Immunopathol 32:3–16

    Article  CAS  PubMed  Google Scholar 

  16. Sfanos KS, Bruno TC, Maris CH et al (2008) Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res 14:3254–3261

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Liu S, Liu F, Zhang B et al (2020) CD4(+) T helper 17 cell response of aged mice promotes prostate cancer cell migration and invasion. Prostate 80:764–776

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Steiner GE, Newman ME, Paikl D et al (2003) Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 56:171–182

    Article  CAS  PubMed  Google Scholar 

  19. Amidfar M, Karami Z, Kheirabadi GR, Afshar H, Esmaeili A (2019) Expression of Bcl-2 and Bax genes in peripheral blood lymphocytes of depressed and nondepressed individuals. J Res Med Sci 24:41

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Wang W, Bergh A, Damber JE (2004) Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate 61:60–72

    Article  CAS  PubMed  Google Scholar 

  21. Golbano JM, Loppez-Aparicio P, Recio MN, Perez-Albarsanz MA (2008) Finasteride induces apoptosis via Bcl-2, Bcl-xL, Bax and caspase-3 proteins in LNCaP human prostate cancer cell line. Int J Oncol 32:919–924

    CAS  PubMed  Google Scholar 

  22. Chen X, Zeng XH, Wang M et al (2018) Bcl2-Like Protein 12 Is Required for the Aberrant T Helper-2 Polarization in the Heart by Enhancing Interleukin-4 Expression and Compromising Apoptotic Machinery in CD4+ T Cells. Circulation 138:2559–2568

    Article  CAS  PubMed  Google Scholar 

  23. Li MG, Liu XY, Liu ZQ et al (2018) Bcl2L12 Contributes to Th2-Biased Inflammation in the Intestinal Mucosa by Regulating CD4(+) T Cell Activities. J Immunol 201:725–733

    Article  CAS  PubMed  Google Scholar 

  24. Qi F, Jiang X, Tong T, Chang H, Li RX (2020) MiR-204 inhibits inflammation and cell apoptosis in retinopathy rats with diabetic retinopathy by regulating Bcl-2 and SIRT1 expressions. Eur Rev Med Pharmacol Sci 24:6486–6493

    CAS  PubMed  Google Scholar 

  25. Russo A, Cardile V, Graziano ACE, Avola R, Bruno M, Rigano D (2018) Involvement of Bax and Bcl-2 in induction of apoptosis by essential oils of three Lebanese salvia species in human prostate cancer cells. Int J Mol Sci 19:292

    Article  PubMed  PubMed Central  Google Scholar 

  26. Konig SM, Rissler V, Terkelsen T, Lambrughi M, Papaleo E (2019) Alterations of the interactome of Bcl-2 proteins in breast cancer at the transcriptional, mutational and structural level. PLoS Comput Biol 15:e1007485

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This research was supported by The Capital Health Research and Development of Special Fund (2020-2-2033).

Author information

Authors and Affiliations

  1. Division of Urology, Department of Urology, Beijing ChaoYang Hospital, Capital Medical University, Beijing, 100020, China

    Yifan Chu, Yun Cui, Dawei Xie, Lei Yang, Siqi Wang & Jianwen Wang

  2. Department of Urology, Beijing Haidian Hospital, Beijing, China

    Mengdong Zhang

  3. Department of Urology, Cancer Hospital of Chinese Academy of Sciences, Beijing, China

    Mingshuai Wang

Authors
  1. Yifan Chu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mengdong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yun Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dawei Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mingshuai Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lei Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Siqi Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jianwen Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

JW and MZ had the idea for and designed the study. YC and MZ wrote the manuscript. MW and SW collected the materials. CY and DX managed experimental data. YC and LY analyzed and explained the experimental data. All the authors contributed to writing of the report.

Corresponding author

Correspondence to Jianwen Wang.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All the procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study. All the procedures performed in studies involving human participants were in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chu, Y., Zhang, M., Cui, Y. et al. The effect of 5-α reductase inhibitor on Th1, Th2, and Th17 cell-related inflammatory response in BPH. World J Urol 41, 1395–1400 (2023). https://doi.org/10.1007/s00345-023-04357-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-023-04357-4

Keywords

Search

Navigation